Across TCGA pan-cancer cohorts, IGHV2-5 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IGHV2-5 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher IGHV2-5 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated IGHV2-5 expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

LUAD, HNSC, and UCEC are the cancer types where IGHV2-5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	III,IV	0.365	0.867	.013	8	view →
HNSC	DFS	Tertile	IV	0.876	0.551	.008	7	view →
UCEC	DFS	Tertile	All	0.794	0.946	.029	4	view →
PDAC	OS	Median	IV	0.911	0.540	.049	3	view →
GBM	DFS	Median	All	0.483	0.273	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: IGHV2-5 tumor-vs-normal RNA expression · all IGHV2-5 data types